Develop precision therapies for genetically defined diseases. Focus on treatments targeting specific genetic mutations. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 22% below its peak. The market has trimmed its expectations for the company.
There is $900.8M in the vault; even if every debt were paid off, $647.6M would remain.
A loss of $328.9M against $0 in annual sales.
The growth engine is running at low revs right now. Report-card grade: 30/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 40/100.
On our five-subject report card, COGT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: COGT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (47/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.